Moderna Stuns Wall Street With Surprise Profit, Raises Outlook
Moderna (MRNA) jumps as Q3 earnings swing to a surprise profit of $0.38/share on strong global vaccine sales and cost cuts.
Stocks · News reference
TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday
U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securitize, Lakefront and others also gained.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Moderna (MRNA) Q3 Earnings and Revenues Top Estimates
Moderna reported quarterly earnings of $0.38 per share, significantly beating the consensus estimate of a loss of $1.1 per share, with a 134.55% earnings surprise. The company posted revenues of $1.31 billion, surpassing estimates by 47.73%. However, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. Moderna shares have gained 718.8% year-to-date, substantially outperforming the S&P 500's 7.4% gain.
Moderna, JFrog, TransMedics, Ubiquiti And Other Big Stocks Moving Higher On Friday
U.S. stocks rose, Nasdaq gained ~400 points. Moderna jumped 9.1% on strong Q3 results and higher FY26 guidance; other stocks rallied on results and deals.
Moderna Just Gave Investors Yet Another Thing to Cheer About
Moderna reported a surprise profitable quarter with $1.31B in revenue (29% YoY growth) and $0.38 EPS, defying analyst expectations of a loss. The company raised full-year guidance and ended with $8.1-8.3B in cash. Its cancer vaccine with Merck showed strong Phase 3 results, reducing melanoma recurrence risk by 42%, while the stock has surged 720% in 2026. However, risks include COVID vaccine sales volatility and significant optimism already priced into the stock.
Piper Sandler Reiterates Neutral on Xeris Biopharma Holdings, Raises Price Target to $12
Pulse Biosciences Presents Six-Month Interim Results from PRECISE-BTN Study
Pulse Biosciences announced positive six-month interim results from its PRECISE-BTN multicenter study evaluating the nPulse Vybrance Percutaneous Electrode System for benign thyroid nodules.